Nivolumab–ipilimumab — exploiting the mutation burden of NSCLCs
Author:
- 27 April 2018
- journal article
- editorial
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 15 (7) , 403
Abstract
No abstract availableThis publication has 2 references indexed in Scilit:
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenNew England Journal of Medicine, 2018
- Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung CancerCancer Cell, 2018